Dysregulated PI3K/AKT and WNT/CTNNB1 signaling in the development and progression of metastatic tumor is mediated via a direct inhibition of beta-catenin degradation following the inhibition of GSK3beta. This evidence concerns the gene CTNNB1 and metastatic neoplasm.